And now for the most expected sale in life sciences...as predicted by many over many years, only question was who.
Drug developer MDS Inc. said Monday it is buying bioanalytical measurement systems maker Molecular Devices Corp. for $615 million in cash. Under terms of the deal, MDS will pay $35.50 per share for all outstanding shares of Molecular Devices. The offer represents a 48.7 percent premium over Molecular Devices' closing price of $23.88 on Friday. The total price includes $585 million to buy outstanding shares plus $30 million for outstanding stock options
MDS Buying Molecular Devices for $615M
- ► 2013 (23)
- ► 2008 (24)
- ▼ 2007 (65)
- ► 2006 (77)